Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2014 1
2015 2
2016 1
2017 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Antibiotic use from formal and informal healthcare providers in the Democratic Republic of Congo: a population-based study in two health zones.
Ingelbeen B, Phanzu DM, Phoba MF, Budiongo MYN, Berhe NM, Kamba FK, Kalonji L, Mbangi B, Hardy L, Tack B, Im J, Heyerdahl LW, Da Luz RI, Bonten MJM, Lunguya O, Jacobs J, Mbala P, van der Sande MAB. Ingelbeen B, et al. Among authors: da luz ri. Clin Microbiol Infect. 2022 Sep;28(9):1272-1277. doi: 10.1016/j.cmi.2022.04.002. Epub 2022 Apr 18. Clin Microbiol Infect. 2022. PMID: 35447342 Free article.
Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.
Matangila JR, Doua JY, Mitashi P, da Luz RI, Lutumba P, Van Geertruyden JP. Matangila JR, et al. Among authors: da luz ri. Int J Antimicrob Agents. 2017 Mar;49(3):339-347. doi: 10.1016/j.ijantimicag.2016.11.017. Epub 2017 Jan 17. Int J Antimicrob Agents. 2017. PMID: 28108368 Clinical Trial.
Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial.
Mavoko HM, Nabasumba C, da Luz RI, Tinto H, D'Alessandro U, Kambugu A, Baraka V, Rosanas-Urgell A, Lutumba P, Van Geertruyden JP. Mavoko HM, et al. Among authors: da luz ri. Lancet Glob Health. 2017 Jan;5(1):e60-e68. doi: 10.1016/S2214-109X(16)30236-4. Epub 2016 Nov 11. Lancet Glob Health. 2017. PMID: 27840069 Free article. Clinical Trial.